Serum klotho is inversely associated with metabolic syndrome in chronic kidney disease: results from the KNOW-CKD study

被引:32
作者
Kim, Hyo Jin [1 ]
Lee, Joongyub [2 ,3 ]
Chae, Dong-Wan [4 ]
Lee, Kyu-Beck [5 ]
Sung, Su Ah [6 ]
Yoo, Tae-Hyun [7 ]
Han, Seung Hyeok [7 ]
Ahn, Curie [8 ]
Oh, Kook-Hwan [8 ]
机构
[1] Dongguk Univ, Coll Med, Dept Internal Med, Gyeongju Si, Gyeongsangbuk D, South Korea
[2] Inha Univ, Sch Med, Incheon, South Korea
[3] Inha Univ Hosp, Dept Prevent & Management, Incheon, South Korea
[4] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnamsi, Gyeonggi Do, South Korea
[5] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Internal Med, Seoul, South Korea
[6] Eulji Univ, Nowon Eulji Med Ctr, Dept Internal Med, Seoul, South Korea
[7] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[8] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, 101 Daehak Ro, Seoul 03080, South Korea
关键词
Chronic kidney disease; Klotho; Metabolic syndrome; CARDIOVASCULAR RISK; OXIDATIVE STRESS; GENE; EXPRESSION; DIAGNOSIS;
D O I
10.1186/s12882-019-1297-y
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Metabolic syndrome (MS) is prevalent in chronic kidney disease (CKD). Klotho, a protein linked to aging, is closely associated with CKD. Each component of MS and klotho has an association. However, little is known about the association between klotho and MS per se. We investigated the association between serum klotho levels and MS using baseline cross-sectional data obtained from a large Korean CKD cohort. Methods: Of the 2238 subjects recruited in the KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD) between 2011 and 2016, 484 patients with missing data on serum klotho and extreme klotho values (values lower than the detectable range or > 6000 pg/mL) or with autosomal dominant polycystic kidney disease patients were excluded. The data of the remaining 1754 subjects were included in the present study. MS was defined using the revised National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III criteria. Serum klotho levels were measured using an enzyme-linked immunosorbent assay. Results: Mean patient age was 54.9 +/- 12.1 years and 1110 (63.3%) were male. The prevalence of MS among all study subjects was 63.7% (n = 1118). The median serum klotho level was 527 pg/mL (interquartile range [IQR]: 418-656 pg/mL). Serum klotho level was significantly lower in MS patients than patients without MS (Median [IQR]; 521 pg/mL [413, 651] vs. 541 pg/mL [427, 676], respectively; P = 0.012). After adjusting for age, sex, estimated glomerular filtration rate, and overt proteinuria, serum klotho was independently associated with MS (adjusted odds ratio [OR], 0.44; 95% confidence interval, 0.23-0.82; P = 0.010). Furthermore, the adjusted OR for MS was found to be significantly increased at serum klotho levels of < 518 pg/mL (receiver operating characteristic curve cut-off value). Conclusions: Serum klotho was inversely associated with the presence of MS in patients with CKD.
引用
收藏
页数:10
相关论文
共 40 条
[1]   Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity [J].
Alberti, K. G. M. M. ;
Eckel, Robert H. ;
Grundy, Scott M. ;
Zimmet, Paul Z. ;
Cleeman, James I. ;
Donato, Karen A. ;
Fruchart, Jean-Charles ;
James, W. Philip T. ;
Loria, Catherine M. ;
Smith, Sidney C., Jr. .
CIRCULATION, 2009, 120 (16) :1640-1645
[2]   Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity [J].
Arking, DE ;
Atzmon, G ;
Arking, A ;
Barzilai, N ;
Dietz, HC .
CIRCULATION RESEARCH, 2005, 96 (04) :412-418
[3]   Circulating Levels of Soluble Klotho and FGF23 in X-Linked Hypophosphatemia: Circadian Variance, Effects of Treatment, and Relationship to Parathyroid Status [J].
Carpenter, Thomas O. ;
Insogna, Karl L. ;
Zhang, Jane H. ;
Ellis, Bruce ;
Nieman, Sherril ;
Simpson, Christine ;
Olear, Elizabeth ;
Gundberg, Caren M. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (11) :E352-E357
[4]  
Causes of death, 1998, AM J KIDNEY DIS S, V32, pS81
[5]   The metabolic syndrome and chronic kidney disease in US adults [J].
Chen, J ;
Muntner, P ;
Hamm, LL ;
Jones, DW ;
Batuman, V ;
Fonseca, V ;
Whelton, PK ;
He, J .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (03) :167-174
[6]  
FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1
[7]   Clinical epidemiology of cardiovascular disease in chronic renal disease [J].
Foley, RN ;
Parfrey, PS ;
Sarnak, MJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :S112-S119
[8]   Diagnosis and management of the metabolic syndrome - An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [J].
Grundy, SM ;
Cleeman, JI ;
Daniels, SR ;
Donato, KA ;
Eckel, RH ;
Franklin, BA ;
Gordon, DJ ;
Krauss, RM ;
Savage, PJ ;
Smith, SC ;
Spertus, JA ;
Costa, F .
CIRCULATION, 2005, 112 (17) :2735-2752
[9]   Does oxidative damage to DNA increase with age? [J].
Hamilton, ML ;
Van Remmen, H ;
Drake, JA ;
Yang, H ;
Guo, ZM ;
Kewitt, K ;
Walter, CA ;
Richardson, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (18) :10469-10474
[10]   A proposal for the cutoff point of waist circumference for the diagnosis of metabolic syndrome in the Japanese population [J].
Hara, K ;
Matsushita, Y ;
Horikoshi, M ;
Yoshiike, N ;
Yokoyama, T ;
Tanaka, H ;
Kadowaki, T .
DIABETES CARE, 2006, 29 (05) :1123-1124